NCT01884623: Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer |
|
|
| Completed | 3 | 82 | Europe | Cetuximab, Methotrexate | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France, Ligue contre le cancer, France, Merck Serono International SA | Head Neck Cancer Squamous Cell Recurrent | 10/21 | 10/21 | | |